Reported 2 days ago
Aristotle Capital Management highlighted Amgen Inc. (NASDAQ:AMGN) in its second quarter 2025 investor letter, noting its robust pipeline and strong sales growth in key therapeutic areas despite facing market pressures. The company has demonstrated resilience by committing to significant U.S. expansions and maintaining innovation in its drug offerings. While recent stock performance has been mixed, with concerns over tariffs and price pressures, there is optimism about Amgen's ability to adapt and grow in a transforming healthcare market.
Source: YAHOO